Last reviewed · How we verify
Epirubicin Hydrochloride for Injection
Epirubicin intercalates into DNA and inhibits topoisomerase II, leading to DNA damage and cell death in rapidly dividing cancer cells.
Epirubicin intercalates into DNA and inhibits topoisomerase II, leading to DNA damage and cell death in rapidly dividing cancer cells. Used for Breast cancer (adjuvant and metastatic), Gastric cancer, Lymphomas.
At a glance
| Generic name | Epirubicin Hydrochloride for Injection |
|---|---|
| Sponsor | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| Drug class | Anthracycline topoisomerase II inhibitor |
| Target | Topoisomerase II, DNA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Epirubicin is an anthracycline chemotherapy agent that inserts itself between DNA base pairs and blocks topoisomerase II-mediated DNA repair, causing double-strand breaks and apoptosis. It is particularly effective against rapidly proliferating cells in solid tumors and hematologic malignancies. The hydrochloride salt formulation is administered intravenously for systemic distribution.
Approved indications
- Breast cancer (adjuvant and metastatic)
- Gastric cancer
- Lymphomas
- Other solid tumors as part of combination chemotherapy regimens
Common side effects
- Myelosuppression (neutropenia, anemia, thrombocytopenia)
- Nausea and vomiting
- Alopecia
- Mucositis
- Cardiotoxicity (dose-dependent)
- Diarrhea
- Fatigue
Key clinical trials
- A Single-Arm, Single-Center, Phase II Clinical Study of Camrelizumab Combined With Radiochemotherapy as Neoadjuvant Therapy for Early-Stage Triple-Negative Breast Cancer (NA)
- A Single-Arm Study on the Efficacy of Sequential Chemoradiotherapy Followed by Surgery in Adult Nasal and Paranasal Sinus Rhabdomyosarcoma
- A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC (PHASE3)
- Study of Neoadjuvant Endocrine Therapy in HR Positive and HER2 Negative Premenopausal Breast Cancer Patients (PHASE2, PHASE3)
- Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy (PHASE2)
- Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer (PHASE2)
- Neoadjuvant Chemotherapy With WH002 in Women With HER2-negative Breast Cancer (PHASE1)
- Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: